Global Hyperammonemia Treatment Market is forecast to register a CAGR of 4.77% through 2033

According to a recently published study by Future Market Insights, the global hyperammonemia treatment market size is expected to reach a valuation of US$ 1,318.05 Million in 2023 and is projected to reach US$ 2,100 Million by 2033, trailing a CAGR of 4.77%.

The rising prevalence of urea cycle disorders and extensive research and development are the primary factors driving the growth of Hyperammonemia treatment market. Growing expansion of infrastructure development, and support from governments are anticipated to influence the market demand. The increasing awareness among masses and growing number of innovative diagnostic approaches are increasing the growth of Hyperammonemia treatment market.

Get Sample PDF@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16383

Additionally, research and development studies highlighting the genetic characterization of Hyperammonemia will help market players align their product development, which will contribute in market expansion. However, complications of long-term therapy, production of these drugs, and challenges in diagnosing are likely to restrict growth of global Hyperammonemia treatment market.

Key Takeaways from the Market Study

• Global hyperammonemia treatment market is expected to grow 1.6x from 2023 to 2033
• US is estimated to lead the market in North America while recording a market share of 48%.
• South Asia is expected to register a 4.2% CAGR with regard to hyperammonemia treatment disbursement
• By treatment type, glycerol phenylbutyrate is estimated to account for a segment share of 35.5% by end of 2033.
• By distribution channel, hospital pharmacies will contribute with a segment share of around 48% by end of the forecast period.
• Developments in gene therapy for the treatment of Hyperammonemia are expected to proliferate product demand.

“Advancements in gene therapy and growing investments in Research & development for treatment of hyperammonemia will bolster product demand”, comments an FMI analyst

Get a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16383

Competitive Landscape

The market is fragmented and moderately competitive. The strategies such as mergers and acquisitions adopted by major market players will boost the studied market growth. The major players in the market are: Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc, Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd, Abbott Laboratories, and Selecta Biosciences, Inc. Some recent developments in this industry are as follows:

• In January 2021, Acer Therapeutics and Relief Therapeutics Holding AG, a biopharmaceutical company, entered into collaboration and license agreement for the worldwide development and commercialization of acer-001, a sodium Phenylbutyrate drug conjugate for the treatment of urea cycle disorders.
• In July 2022, Versantis AG revealed that the US Food and Drug Administration (FDA) designated its major product candidate VS-01, an ammonia clearance enhancer, a rare pediatric disease designation for the treatment of urea cycle disorders.
• In October 2021, According to Acer Therapeutics Inc. and its collaboration partner, RELIEF THERAPEUTICS (UCDs). The US Food and Drug Administration (FDA) accepted the submission of the New Drug Application (NDA) for the drug ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders.
• In January 2021, Recordati Rare Diseases Inc. received the US Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia

Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16383

Key Segments Profiled in the Hyperammonemia Treatment Market Industry Survey

By Treatment Type:

• Amino Acid Supplements
• Sodium Phenylbutyrate
• Glycerol Phenylbutyrate
• Sodium Benzoate
• Others

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs